China Condemns US Plan to Restrict Biotech Investment

Beijing publicly condemned a US proposal to restrict investments in Chinese biotech firms, calling it contrary to mutual interests. The move signals escalating US-China tech decoupling extending into biotechnology, with potential implications for cross-border capital flows and sector supply chains. The proposal's scope and timeline remain unclear, and China's response suggests possible retaliatory measures.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works